Feminizing hormone therapy replaces a testosterone-dominant hormonal profile with an oestrogen-dominant one. In practice that usually means oestrogen plus a medication to suppress testosterone, with doses adjusted against blood levels over months.
It is the foundation of most transfeminine transitions and the only intervention on this site that changes the whole body at once. It is also long-term medical treatment, not a course — it requires monitoring for life, and some of what it does cannot be undone.
How much does feminizing hormone therapy cost in 2026?
Annual cost of medication, consultations and monitoring for self-funded care. Indicative figures, not quotes.
| Country | Typical annual cost | Approx. in EUR |
|---|---|---|
| United States (self-funded) | $2,200 – $5,400 | €2,000 – €5,000 |
| Canada (self-funded) | C$2,600 – C$5,900 | €1,800 – €4,000 |
| United Kingdom (private clinic) | £1,600 – £3,400 | €1,900 – €4,000 |
| Turkey (Hetzner Health partner physicians) | €700 – €1,500 | €700 – €1,500 |
| Usually included | Usually extra |
|---|---|
| Initial consultation and examination | Flights and accommodation |
| Baseline blood panel | Medication itself, prescribed and dispensed locally |
| Prescription and dose titration | Psychological assessment or letters, where required |
| Monitoring bloods at 3, 6 and 12 months during visits | Sperm banking and storage fees |
| Written treatment and monitoring plan for your doctor at home | Hair removal, voice therapy and any surgery |
| Interpreter for appointments | Ongoing monitoring at home between visits |
Budget for monitoring, not just medication. The medication is cheap almost everywhere; the blood tests and reviews are what make it safe, and they continue indefinitely.
About these figures: indicative ranges for budgeting, not an offer. See our Medical Disclaimer.
What changes, and when?
| Change | Starts | Maximum effect | Permanent if you stop? |
|---|---|---|---|
| Reduced oily skin and acne | 1–3 months | 1–2 years | No |
| Reduced libido and spontaneous erections | 1–3 months | 3–6 months | No |
| Breast tenderness and budding | 2–6 months | — | — |
| Softening of skin texture | 3–6 months | 1–2 years | No |
| Body fat redistribution to hips and thighs | 3–6 months | 2–5 years | No |
| Breast growth | 3–6 months | 2–3 years | Yes — does not reverse |
| Reduced muscle mass and strength | 3–6 months | 1–2 years | No |
| Slowed and thinner body hair | 6–12 months | 3+ years | No |
| Reduced testicular volume | 3–6 months | 2–3 years | Partly |
| Reduced or absent sperm production | 3–6 months | Variable | Often permanent |
| Scalp hair loss slowed or halted | 1–3 months | 1–2 years | No |
What hormones will not change:
| Unchanged | What does change it |
|---|---|
| Voice pitch | Voice therapy and voice surgery |
| Facial bone structure — brow, jaw, chin | Facial feminization surgery |
| Adam’s apple prominence | Tracheal shave |
| Height and skeletal frame | Nothing |
| Shoulder width | Training change, or clavicle surgery |
| Beard hair (thins but persists) | Electrolysis or laser hair removal |
| A hairline that has already receded | Hair transplant or hairline lowering |
What medications are used?
| Class | Common options | Notes |
|---|---|---|
| Oestrogen — transdermal | Oestradiol patches, gel | Preferred where thrombotic risk is a concern; avoids first-pass liver metabolism |
| Oestrogen — oral | Oestradiol valerate, oestradiol hemihydrate | Convenient; slightly higher venous thromboembolism risk than transdermal |
| Oestrogen — injectable | Oestradiol valerate or cypionate | Fewer doses, but level peaks and troughs |
| Anti-androgen | Spironolactone | Requires potassium monitoring; diuretic effect |
| Anti-androgen | Cyproterone acetate | Effective at low doses; liver and prolactin monitoring; dose-related meningioma risk means low doses are now standard |
| Androgen suppression | GnRH analogues | Highly effective, expensive, used more in some health systems than others |
| Progestogen | Micronised progesterone | Used by some clinicians; evidence for added breast development is limited and debated |
Never use ethinylestradiol. The oestrogen found in combined contraceptive pills carries a substantially higher clotting risk and has no place in gender-affirming hormone therapy. If a source offers it to you, that source is not safe.
Who is a good candidate?
| You are likely suitable if | Why it matters |
|---|---|
| You have a documented assessment consistent with WPATH or your country’s standards | Required by most reputable prescribers |
| You have capacity to give informed consent | The consequences include permanent changes |
| Your fertility decision has been made and acted on | Sperm banking cannot be done retrospectively |
| You have no uncontrolled cardiovascular or thrombotic condition | Oestrogen affects clotting risk |
| You do not smoke, or are willing to stop | Smoking combined with oestrogen sharply raises clotting risk |
| You can attend regular blood monitoring | This is what makes long-term therapy safe |
| You have, or will have, a prescriber at home | Continuity of care matters more than where you start |
When should hormone therapy be delayed or modified?
- A history of venous thromboembolism, stroke or heart attack — not always an absolute barrier, but requires specialist input and usually transdermal oestrogen at conservative doses.
- Active hormone-sensitive cancer, including breast cancer.
- Severe liver disease, until assessed.
- Uncontrolled hypertension, diabetes or very high lipids, until managed.
- A known thrombophilia such as factor V Leiden.
- Current smoking, particularly over 35 — this substantially compounds thrombotic risk.
- Fertility not yet discussed or acted on — this is a reason to pause for weeks, not to refuse.
- A prolactinoma or a history of meningioma, which affects which anti-androgen can be used.
None of these mean hormone therapy is impossible. Most mean the route, the dose or the monitoring changes.
What monitoring is required?
| Timepoint | What is checked |
|---|---|
| Baseline | Oestradiol, testosterone, full blood count, liver and kidney function, lipids, glucose or HbA1c, prolactin; blood pressure and weight |
| 3 months | Oestradiol and testosterone levels, side effects, potassium if on spironolactone, liver function if on cyproterone |
| 6 months | As above, plus clinical response review and dose adjustment |
| 12 months | Full panel repeated; discussion of progress and expectations |
| Annually thereafter | Hormone levels, liver and kidney function, lipids, prolactin as indicated, blood pressure |
| Ongoing | Age-appropriate screening; breast awareness once tissue develops; prostate remains present after bottom surgery |
The target is a hormone profile, not a maximum dose. Most guidelines aim for oestradiol and testosterone levels in the typical premenopausal female range. Higher oestrogen does not produce more breast growth — it produces more thrombotic risk. Dose escalation beyond target is one of the commonest and most dangerous things people do when self-medicating.
Fertility: the decision that cannot wait
Sperm production falls within months of starting therapy, often to zero, and may not recover after prolonged treatment even if hormones are stopped. Sperm banking has to happen before you start.
| Option | When | Notes |
|---|---|---|
| Sperm cryopreservation | Before starting hormones | The straightforward route; storage fees are ongoing |
| Pausing hormones to bank later | Months of pause required | Recovery is unpredictable and the pause is difficult |
| Surgical sperm retrieval | After hormones | Possible in some cases, more invasive, not guaranteed |
| Accepting infertility | — | A valid choice, but it should be an explicit one |
Hormone therapy is also not contraception. Pregnancy remains possible with a partner who can conceive until sperm production is confirmed absent.
What are the risks?
- Venous thromboembolism — deep vein thrombosis and pulmonary embolism; the most important risk, higher with oral oestrogen, smoking, obesity and age
- Increased risk of stroke and cardiovascular events, particularly with other risk factors
- Elevated triglycerides and changes to the lipid profile
- Raised blood pressure
- Gallstones
- Elevated prolactin, and rarely prolactinoma
- Meningioma, associated with cyproterone acetate in a dose-dependent way
- High potassium with spironolactone, which can affect heart rhythm
- Liver enzyme abnormalities
- Mood changes, in both directions
- Reduced libido and erectile function — expected, and welcome for many, unwelcome for some
- Permanent infertility
- Permanent breast development, which does not reverse
- Breast cancer risk, which appears higher than in cisgender men and lower than in cisgender women, and warrants screening awareness
This list is not exhaustive. Seek emergency care for calf pain or swelling, chest pain, breathlessness, sudden severe headache, visual disturbance, or weakness on one side of the body. Your individual risk profile belongs in a documented discussion with your prescriber.
Do not self-medicate. Unmonitored hormone therapy from online sources is the single most common source of serious harm in transfeminine care — wrong medication, wrong doses, no clotting risk assessment, no blood monitoring. The medication costs almost nothing; the supervision is what you are paying for.
How does it fit with surgery?
| Procedure | Relationship to hormone therapy |
|---|---|
| Top surgery | Requires at least 12 months of hormones so natural growth is complete |
| Bottom surgery | Usually 12 months of hormones; oestrogen often paused around the operation |
| Facial feminization | No hormone requirement; bone does not respond to hormones |
| Voice surgery | No hormone requirement; hormones do not change pitch |
| Hair transplant | Hormones should be stabilising hair loss first |
| Any long operation | Your surgeon may ask you to pause oestrogen for 1–4 weeks; agree it with your prescriber |
What results can you expect?
Over two to three years, softer skin, fat redistributed towards the hips and thighs, reduced muscle bulk, thinner body hair, breast development typically to an A or small B cup, and a hormonal profile in the typical female range. Many people also report changes in emotional experience, though these are harder to measure.
What it will not do is change your skeleton, your voice or your hairline. Hormone therapy is the foundation that the rest of transfeminine care is built on, not a substitute for it.
Comparison photographs online are unreliable guides. Response varies enormously with genetics, age at starting and body composition, and the timelines people post are their own.
How Hetzner Health arranges the process
- Assessment — medical history, examination and an assessment consistent with WPATH Standards of Care, with a partner physician.
- Fertility conversation first — raised explicitly before anything is prescribed, because it cannot be revisited.
- Risk assessment — thrombotic, cardiovascular and liver risk, which determines route and dose.
- Baseline bloods and a written treatment plan with target hormone levels stated numerically.
- Prescription and titration, with review at three, six and twelve months.
- Continuity at home — we provide a written plan and monitoring schedule for your own doctor, and we ask you to have one. We will not manage hormone therapy remotely without examination and blood tests.
- Coordination with surgery — if you are planning procedures, your prescriber and surgeon agree any peri-operative pause together, not you alone.
Before you decide: this page is general information about a class of medications and does not replace medical advice. Feminizing hormone therapy is prescription treatment with permanent effects and real risks, and it requires a prescriber who examines you, monitors your bloods and remains available to you over years.